(143 days)
The FOREX Corporation, OPTIMA™ posterior spinal fixation device is a pedicle screw system indicated for the treatment of severe Spondylolisthesis (Grade 3 and 4) of the L5-S1 vertebra in skeletally mature patients receiving fusion by autogenous bone graft having implants attached to the lumbar and sacral spine (L3 to sacrum) with removal of the implants after the attainment of a solid fusion.
In addition, the OPTIMA™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar and sacral spine: degenerative Spondylolisthesis with objective evidence of neurological impairment, fracture, dislocation, scoliosis, kyphosis, spinal tumor and failed previous fusion (pseudarthrosis).
When used as an anterior screw fixation system or a posterior hook and sacral/iliac screw fixation system, the OPTIMA™ is indicated for patients with degenerative disc disease which is defined as back pain of the discogenic origin with degeneration of the disc confirmed by history and radiographic studies, Spondylolisthesis, fracture, spinal stenosis, spinal deformities such as scoliosis, kyphosis, lordosis, tumor, pseudoarthrosis, or revision of failed fusion attempts.
The OPTIMATM Spinal System is a top-loading multiple component, anterior / posterior spinal fixation system which consists of pedicle screws, rods, set screws, connectors, and a transverse (cross) linking mechanism. The OPTIMA™ system will allow surgeons to build a spinal implant construct to stabilize and promote spinal fusion. The OPTIMA™ implant system components are supplied non-sterile are single use and are fabricated from titanium alloy (Ti-6Al-4V ELI) that conforms to ASTM F 136. Various sizes of these implants are available. Specialized instruments made from surgical grade stainless steel are available for the application and removal of the OPTIMA™ system.
The information provided describes the FOREX Corporation OPTIMA™ Spinal System, a medical device. The document primarily focuses on its 510(k) submission for market clearance, establishing substantial equivalence to predicate devices, and thus does not directly address typical acceptance criteria and performance studies commonly seen in AI/ML device submissions.
Instead, the "acceptance criteria" for this device are met through demonstrating substantial equivalence to already legally marketed predicate devices, and the "study" proving this involves bench testing.
Here's how to frame the requested information based on the provided text:
Acceptance Criteria and Device Performance
| Acceptance Criteria (Demonstration of Equivalence) | Reported Device Performance (Bench Testing Result) |
|---|---|
| Equivalence in materials to predicate devices | Bench testing in accordance with ASTM F1717 demonstrates equivalence to predicate devices. |
| Equivalence in design to predicate devices | Bench testing in accordance with ASTM F1717 demonstrates equivalence to predicate devices. |
| Equivalence in operational principles to predicate devices | Bench testing in accordance with ASTM F1717 demonstrates equivalence to predicate devices. |
| Equivalence in indications for use to predicate devices | Bench testing in accordance with ASTM F1717 demonstrates equivalence to predicate devices. |
Study Details
-
Sample size used for the test set and the data provenance:
- The document states "Bench testing as listed in Section XII". Section XII is not provided, so the specific sample size for the bench tests is not specified in the given text.
- The data provenance is from bench testing, meaning in-vitro mechanical and material tests, not patient data.
-
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- This question is not applicable in the context of this 510(k) submission. Bench testing for mechanical properties does not typically involve human expert adjudication for ground truth. The "ground truth" for these tests would be the measured physical properties compared against established engineering standards (ASTM F1717) and the properties of predicate devices.
-
Adjudication method (e.g. 2+1, 3+1, none) for the test set:
- This is not applicable. Bench testing results are typically objectively measured and do not require adjudication by experts in the same way clinical or imaging studies might.
-
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No, an MRMC comparative effectiveness study was not done. This is a spinal implant system, not an AI or imaging device that would involve human readers.
-
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- No, a standalone algorithm performance study was not done. This device is a physical medical implant, not a software algorithm.
-
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- The "ground truth" for the bench testing was established by standardized mechanical testing protocols (ASTM F1717) and engineering specifications. The performance was compared to that of legally marketed predicate devices.
-
The sample size for the training set:
- This is not applicable. This is a physical medical device, not a machine learning model, so there is no "training set."
-
How the ground truth for the training set was established:
- This is not applicable as there is no training set for a physical implant device.
{0}------------------------------------------------
JUN 2 0 2002
Forex Corporation
6132 South 380 West . Suite # 200 . Murray, Utah 84107 . Phone: (801) 262-3100 62-3151
510(k) SUMMARY
The following 510(k) summary is being submitted as required by 21 CFR 807.92(a):
Submission Information:
Contact:
Robert Malone Corporate Manager, Regulatory Affairs and Quality Assurance
Sponsor:
FOREX Corporation 6132 South 380 West Murray, UT 84107 Phone: 801.262.3100 Fax: 801.262.3151
Date Prepared:
May 20, 2002
Device Identification:
Trade Name: FOREX Corporation, OPTIMA™, Spinal System
Common Name:
Classification Name:
. Pedical Screw Spinal Fixation System
Spinal Pedical Screw (MNI) per 21 CFR § 888.3070
Spondylolisthesis Spinal Fixation Device System (MNH) per 21 CFR § 888.3070
Spinal Intervertebral Body Fixation Orthosis (KWQ) per 21 CFR § 888.3060
Substantially Equivalent Predicate Legally Marketed Devices:
Micron Precision Engineering, AMT Spinal System - KWP, MNH -- (K002059) Stryker® Spine, Xia™ Spinal System -- MNH, MNI, KWQ -- (K001319)
The substantial equivalence of this device is based on equivalence in intended use, materials, designs and operational principles to the above listed predicate devices.
Device Description:
The OPTIMATM Spinal System is a top-loading multiple component, anterior / posterior spinal fixation system which consists of pedicle screws, rods, set screws, connectors, and a transverse (cross) linking mechanism.
{1}------------------------------------------------
Ko20279
$$r^2/2$$
The OPTIMA™ system will allow surgeons to build a spinal implant construct to stabilize and promote spinal fusion. The OPTIMA™ implant system components are supplied non-sterile are single use and are fabricated from titanium alloy (Ti-6Al-4V ELI) that conforms to ASTM F 136. Various sizes of these implants are available. Specialized instruments made from surgical grade stainless steel are available for the application and removal of the OPTIMA™ system.
Indications for Use:
The FOREX Corporation, OPTIMATM posterior spinal fixation device is a pedicle screw system indicated for the treatment of severe Spondylolisthesis (Grade 3 and 4) of the L5-S1 vertebra in skeletally mature patients receiving fusion bv autogenous bone graft having implants attached to the lumbar and sacral spine (L3 to sacrum) with removal of the implants after the attainment of a solid fusion.
In addition, the OPTIMA™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar and sacral spine: degenerative Spondylolisthesis with objective evidence of neurological impairment, fracture, dislocation, scoliosis, kyphosis, spinal tumor and failed previous fusion (pseudarthrosis).
When used as an anterior screw fixation system or a posterior hook and sacral/iliac screw fixation system, the OPTIMA™ is indicated for patients with degenerative disc disease which is defined as back pain of the discogenic origin with degeneration of the disc confirmed by history and radiographic studies, Spondylolisthesis, fracture, spinal stenosis, spinal deformities such as scoliosis, kyphosis, lordosis, tumor, pseudoarthrosis, or revision of failed fusion attempts.
Statement of Technological Comparison:
The subject spinal implant system is substantially equivalent to the above listed predicate devices in terms of materials, design, indications for use and operational principles.
Performance Data:
Bench testing as listed in Section XII which was conducted in accordance with ASTM F1717 demonstrates equivalence to the above listed predicate devices.
{2}------------------------------------------------
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 .
JUN 2 0 2002
Mr. Robert Malone Corporate Manager, Regulatory Affairs and Quality Assurance FOREX Corporation 6132 South 380 West Suite 200 Murray, Utah 84107
Re: K020279
Trade Name: FOREX Corporation, OPTIMA™ Spinal System Regulatory Number: 21 CFR 888.3070 and 21 CFR 888.3060 Regulatory Name: Pedicle screw spinal system, Spinal intervertebral body fixation orthosis Regulatory Class: II Product Code: MNI, MNH, KWQ Dated: April 23, 2002 Received: April 24, 2002
Dear Mr. Malone:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
Page 2 - Mr. Robert Malone
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely vours.
Celia M. Witten, Ph.D., M.D. Director Division of General. Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
SECTION II
INDICATIONS for USE STATEMENT
510(k) Number (if known): ¥(220279
Device Name: FOREX Corporation, OPTIMA™ Spinal System.
Indications for Use: The FOREX Corporation, OPTIMA™ posterior spinal fixation device is a pedicle screw system indicated for the treatment of severe Spondylolisthesis (Grade 3 and 4) of the L5-S1 vertebra in skeletally mature patients receiving fusion by autogenous bone graft having implants attached to the lumbar and sacral spine (L3 to sacrum) with removal of the implants after the attainment of a solid fusion.
In addition, the OPTIMA™ is intended to provide immobilization and stabilization of spinal seaments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar and sacral spine: degenerative Spondylolisthesis with objective evidence of neurological impairment, fracture, dislocation, scoliosis, kyphosis, spinal tumor and failed previous fusion (pseudarthrosis).
When used as an anterior screw fixation system or a posterior hook and sacral/iliac screw fixation system, the OPTIMA™ is indicated for patients with degenerative disc disease which is defined as back pain of the discogenic origin with degeneration of the disc confirmed by history and radiographic studies, Spondylolisthesis, fracture, spinal stenosis, spinal deformities such as scoliosis, kyphosis, lordosis, tumor, pseudoarthrosis, or revision of failed fusion attempts.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | |
|---|---|
| for Mark A Milkerson | |
| (Division Sign-Off) | |
| Division of General, Restorativeand Neurological Devices | |
| 510(k) Number | K020279 |
| Prescription Use | |
| OR Over-the-Counter Use (Per 21 CFR 801.109)(Optional Format 1-2-96) |
N/A